articleThe LancetJul 28, 2014Closed access

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Texas Liver Institute · The University of Texas Health Science Center at San Antonio · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

817
total citations
FWCI
83.86
Percentile
100%
References
17
Citations per year

Authors

22

Topics & keywords

Keywords
  • Simeprevir
  • Ribavirin
  • Medicine
  • Sofosbuvir
  • Internal medicine
  • Cohort
  • Pegylated interferon
  • Adverse effect
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding